![6,6',7,7'-Tetrakis(2-methoxyethoxy)-4H-[3,4'-biquinazolin]-4-one](https://veeprho.com/wp-content/uploads/2022/07/6-6-7-7-Tetrakis2-methoxyethoxy-4H-5B3-4-biquinazolin5D-4-one.png)
6,6′,7,7′-Tetrakis(2-methoxyethoxy)-4H-[3,4′-biquinazolin]-4-one
6,6′,7,7′-Tetrakis(2-methoxyethoxy)-4H-[3,4′-biquinazolin]-4-one is an impurity of Erlotinib is used to treat certain types of non-small cell lung cancer that has spread to nearby tissues or other parts of the body in patients who have already been treated with at least one other chemotherapy medication. Erlotinib is in a class of medications called kinase inhibitors.
Additional information on 6 | 6' | 7 | 7'-Tetrakis(2-methoxyethoxy)-4H-[3 | 4'-biquinazolin]-4-one
Catalogue No.
VE008800
CAS No.
N/A
Molecular Formula
C28H34N4O9
Molecular Weight
570.59 g/mol
Parent drug
Erlotinib
IUPAC Name
6, 6', 7, 7'-Tetrakis(2-methoxyethoxy)-4H-[3, 4'-biquinazolin]-4-one
Synonyms
N/A
References
“Erlotinib: MedlinePlus Drug Information.” Medlineplus.gov, 2017, medlineplus.gov/druginfo/meds/a605008.html.
Status
In-stock
